December 1, 2003
Par Pharmaceutical to Begin Shipment of Metformin Hydrochloride Extended-Release Tablets

November 6, 2003
Par Pharmaceutical Announces Joint Development Agreement with Glatt

November 4, 2003
Pharmaceutical Resources to Present at CIBC World Markets Fourteenth Annual Healthcare Conference

October 20, 2003
Pharmaceutical Resources Announces Equity Investment In Advancis Pharmaceutical Corporation

October 9, 2003
Stephen J. Mock to Join Pharmaceutical Resources as Vice President, Corporate Affairs

September 30, 2003
Par Pharmaceutical Provides Update on Paroxetine Sales

September 29, 2003
Pharmaceutical Resources Announces Exercise of $40 Million Option to Purchase Senior Subordinated Convertible Notes

September 25, 2003
Pharmaceutical Resources Prices $160 Million Senior Subordinated Convertible Notes Offering; Purchased Call Options and Sold Warrants Offset Dilution Up to a Stock Price of $105.20

September 24, 2003
Pharmaceutical Resources Announces Proposed $150 Million Senior Subordinated Convertible Notes Offering

September 24, 2003
Pharmaceutical Resources Files Form 8-K

September 16, 2003
Par Pharmaceutical Begins Shipment of Nefazodone Hydrochloride Tablets

September 16, 2003
Pharmaceutical Resources, Inc. Elects Scott Tarriff President and Chief Executive Officer; Mark Auerbach Elected Executive Chairman of the Board

September 8, 2003
Par Pharmaceutical Begins Shipment of Generic Paroxetine HCl Immediate Release Tablets in U.S. Market

September 5, 2003
Par Pharmaceutical Licenses Clarithromycin XL (Abbott's Biaxin XL®) From Advancis Pharmaceutical Corporation

September 3, 2003
Pharmaceutical Resources to Present at Bear Stearns 16th Annual Healthcare Conference

September 2, 2003
Par Pharmaceutical Begins Shipment of Ofloxacin Tablets

September 2, 2003
Par Pharmaceutical Announces Agreement With Bristol-Myers Squibb For Megace®

August 4, 2003
Pharmaceutical Resources Loratidine 10 mg OTC to Commence Marketing Shortly

July 16, 2003
Pharmaceutical Resources Announces Court Victory in Ribavirin Litigation

July 15, 2003
Pharmaceutical Resources Has Two Additional Patents Issued Covering Megestrol Oral Suspension Formulation

July 7, 2003
Par Pharmaceutical Announces Licensing Agreement With Paddock Laboratories

June 20, 2003
Pharmaceutical Resources Begins Shipment of Mirtazapine Tablets

June 19, 2003
Pharmaceutical Resources Announces Sawyer to Retire

May 30, 2003
Pharmaceutical Resources to Present at UBS Warburg Global Specialty Pharmaceuticals Conference

May 28, 2003
Par Pharmaceutical Begins Shipment of Torsemide

May 19, 2003
Pharmaceutical Resources To Present At Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference

May 12, 2003
Par Pharmaceutical, Inc. Announces Launch of Generic Paroxetine Hydrochloride Immediate Release Tablets in Puerto Rico

April 24, 2003
Pharmaceutical Resources to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference

March 26, 2003
Par Pharmaceutical Licenses Torsemide from Roche

February 27, 2003
Pharmaceutical Resources to Present at Lehman Brothers Healthcare Conference

February 7, 2003
Settlement is Reached with Schering Regarding Ribavirin (Rebetol®)

January 23, 2003
Pharmaceutical Resources To Present At U.S. Bancorp Piper Jaffray Health Care Conference

Archived copies of news releases issued since January 2003 are available on line, grouped by year of release: